Utah Medical Products, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Financial amounts below are in U.S. dollars unless stated otherwise.
Business context and key financial results
UTMD manufactures and markets specialty medical devices. Results reflect lower sales to a major OEM customer, supply constraints, higher litigation costs and increased interest income on cash balances.
| Metric | Q2 2023 | Q2 2022 | 1H 2023 | 1H 2022 |
|---|---|---|---|---|
| Net sales | $12.866m | $13.428m | $25.386m | $25.752m |
| Gross profit | $7.739m | $8.151m | $15.581m | $15.683m |
| Operating income | $4.425m | $5.057m | $8.864m | $9.579m |
| Income before taxes | $5.172m | $5.199m | $10.292m* | $9.729m |
| Net income | $4.200m | $4.103m | $8.414m | $7.638m |
| Diluted EPS | $1.15 | $1.12 | $2.31 | $2.09 |
Margins: Gross margin was 60.1% in Q2 and 61.4% in 1H, versus 60.7% and 60.9% a year earlier. Operating margin was 34.4% and 34.9%, versus 37.7% and 37.2%. Net margin increased to 32.6% and 33.1%, from 30.6% and 29.7%.
Cash flow and balance sheet: First-half operating cash flow was $11.828m, compared with $9.878m. Investing cash outflow was $0.363m, mainly capital expenditures; financing cash outflow was $2.059m, including $2.140m of dividends. Cash and investments increased to $84.619m from $75.052m at year-end. Total liabilities were $8.714m; management reported no debt. Working capital was $93.663m and the current ratio was 19.2.
Material changes and management commentary
- Q2 sales fell 4.2%; first-half sales fell 1.4%. First-half overseas sales grew 12.5% in reported dollars, while U.S. domestic sales declined 10.2%. A stronger U.S. dollar reduced first-half sales by $0.188m, according to management.
- The decline in sales was driven principally by lower pressure-monitoring sales to the largest OEM customer. Management also cited shortages of raw materials and limited third-party sterilization capacity, which constrained direct U.S. demand.
- First-half operating income declined 7.5%, including $0.463m of higher litigation expense. Higher interest income—$1.236m more in 1H than in 2022—helped lift pretax income and net income despite lower operating income.
- Management said first-half gross margin benefited from price increases and remained consistent with long-term profitability goals. Higher manufacturing overhead and employee compensation weighed on Q2 margin.
- First-half operating cash flow improved, supported by net income and collections of receivables, partly offset by increased inventory and lower accrued liabilities. Inventory increased $1.304m from year-end.
Outlook, risks and unusual items
- Management expects full-year 2023 revenue near the low end of its original $50m–$52m projection, or about 5% below 2022, citing weaker demand from the largest OEM customer. It expects 2023 operating income to be significantly below 2022, but believes higher interest income and cash balances can allow net income and EPS to at least match 2022.
- The company is involved in U.S. litigation concerning the safety of the Filshie Clip System. The product remains approved by the FDA as safe and effective. Litigation expenses were a material operating expense; ultimate outcomes and costs are uncertain.
- Other disclosed risks include continued supply-chain and sterilization constraints, foreign-exchange movements, regulatory burdens, product-liability exposure, reliance on distributors and the potential effect of healthcare-market changes.
- Cash deployment priorities include investment in capacity, technology or acquisitions, and returning excess cash through dividends or share repurchases when management considers the share price attractive. No shares were repurchased in 1H 2023.
- The filing reports no material changes in accounting policies, no subsequent events requiring disclosure, and effective disclosure controls as of June 30, 2023.
Important facts for investors to verify
- Whether demand from the largest OEM customer stabilizes and whether the full-year revenue outlook remains achievable.
- Progress in resolving raw-material and third-party sterilization constraints, and the resulting impact on U.S. sales and inventory.
- Developments, potential exposure and future legal costs related to Filshie Clip product-liability claims.
- Whether higher interest income can continue to offset weaker operating income as interest rates and cash balances change.
- The 1H pretax-income figure: the income statement reports $10.292m, while MD&A states $10.291m; the filing text does not provide a clear reconciliation.
*The 1H income-statement table reports $10.292m; MD&A reports $10.291m.